The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…

The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…
Will Boggs, MD |
NEW YORK (Reuters Health)—Long-term rituximab use lowers the chance of relapse of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), compared with standard maintenance therapy, according to a report from the MAINRITSAN3 randomized trial. “Physicians should consider AAV to be a long-lasting, chronic disease which requires maintenance therapy,” says Dr. Pierre Charles of Cochin Hospital, Paris…
Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis…
Julie Steenhuysen |
CHICAGO (Reuters)—Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on May 28. The preliminary results suggest doctors may want to refrain from…
Lisa Rapaport |
(Reuters Health)—U.S. commercial health plans only covered biosimilar treatments as preferred products in 14% of coverage decisions last year, according to an analysis of publicly available data on coverage decisions.1 Researchers examined records from the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database, which has information on coverage decisions made by 17 of…
Marilynn Larkin |
NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis. However, because the study found trends toward increased melanoma rates with long-term therapy, “a clinically meaningful increase in risk cannot…
According to a new study, the prevalence of anti-nuclear antibodies (ANAs), the most common biomarker of autoimmunity in the U.S., has increased considerably in recent years among adolescents aged 12–19 years, in both sexes (especially in men), older adults (age ≥50 years) and non-Hispanic whites…
Reuters Staff |
ZURICH (Reuters)—The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine (HCQ), probably by mid-June, after safety concerns prompted the group to suspend the malaria drug’s use in a trial on COVID-19 patients. U.S. President Donald Trump and others have pushed HCQ as a possible coronavirus treatment, but the WHO…
Josh Horwitz & Brenda Goh |
SHANGHAI (Reuters)—China’s health tracking QR codes, which have played a key part in the country’s successful containment of COVID-19, now look set to play a much broader role in daily life as local authorities dream up new uses for the technology. Embedded in the popular WeChat and Alipay smartphone apps, the codes use self-reported and…
Lisa Rappaport |
(Reuters Health)—Most Medicare Advantage plans are not offering chronically ill enrollees supplemental benefits to address social needs, which were added to the government health program in 2018 in an effort to improve health outcomes and achieve cost savings, a U.S. study suggests.1 Researchers examined publicly available data on benefits and plan design for Medicare Advantage…